Every Form 4 that 20/20 Biolabs Inc (AIDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AIDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIDX filings page.
20/20 Biolabs, Inc. granted Chief Financial Officer Alan B. Bergman a stock option covering 100,000 shares of common stock. The option has an exercise price of $1.88 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market purchase.
According to the vesting terms, 25,000 shares under the option vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months, as long as he continues to serve the company.
20/20 Biolabs, Inc. Chief Operating Officer Zhou Jiming received a grant of stock options covering 150,000 shares of Common Stock. The options have an exercise price of $1.88 per share, were granted on April 2, 2026, and expire on April 2, 2036. Following this grant, Zhou holds 150,000 stock options directly.
20/20 Biolabs, Inc. reported that Chief Executive Officer Jonathan M. Cohen received a grant of stock options covering 352,936 shares of common stock. The options were granted at an exercise price of $0.0000 per share and are held directly.
According to the terms, these options vest in equal quarterly installments over four years, contingent on Cohen’s continued service with the company. After this grant, he holds stock options for 352,936 shares in total, aligning his compensation more closely with the company’s long-term performance.